Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
Laura M. Spring(Massachusetts General Hospital), Aditya Bardia(Harvard University), Rachel O. Abelman(Massachusetts General Hospital), Veerle Bossuyt(Harvard University), Paula D. Ryan(Massachusetts General Hospital), Beverly Moy(Massachusetts General Hospital), Therese M. Mulvey(Sidney Kimmel Cancer Center), Ana C. Garrido-Castro(Harvard University), Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Amy Comander(Harvard University), Sarah A. McLaughlin(Lawrence Berkeley National Laboratory), Nadine Tung(Beth Israel Deaconess Medical Center), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Sara M. Tolaney(Dana-Farber Cancer Institute), Shyamala Maheswaran(Harvard University), Aron S. Rosenstock(Harvard University), Lorenzo Trippa(Harvard University), Louise Ryan(Harvard University), Bing Wu(Harvard University), Filipa Lynce(Georgetown University), Edward Abraham(University of Alabama at Birmingham), Steven J. Isakoff(Harvard University)
Cited by 75
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k